Avalo Director Gets Long-Term Incentive Package Amid Company Growth Plans

Rhea-AI Filing Summary

Director Rita Jain of Avalo Therapeutics (AVTX) received a stock option grant on June 17, 2025, according to a Form 4 filing. The key details include:

• Granted 40,200 stock options to purchase common stock at an exercise price of $4.47 per share
• Options will vest in three equal installments on the first, second, and third anniversary of the grant date
• Options expire on June 17, 2035
• Vesting is contingent on continued service as director

This equity compensation grant appears to be part of the company's director compensation program. The filing was signed by Donald R. Reynolds via power of attorney on June 18, 2025. This transaction represents a new position for the director, as no prior holdings were reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jain Rita

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.47	06/17/2025		A		40,200		(1)	06/17/2035	Common Stock	40,200	$0	40,200	D

Explanation of Responses:

1. The stock option vests in three substantially equal installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date.

	/s/ Donald R. Reynolds, by Power of Attorney	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did Rita Jain receive from AVTX on June 17, 2025?

Rita Jain received 40,200 stock options (right to buy) from Avalo Therapeutics (AVTX) on June 17, 2025, with an exercise price of $4.47 per share.

What is the vesting schedule for AVTX director Rita Jain's stock options granted in June 2025?

The stock options vest in three equal installments on the first, second, and third anniversary of the grant date (June 17, 2025), subject to Rita Jain's continued service as an Eligible Director on each vesting date.

When do Rita Jain's AVTX stock options expire?

Rita Jain's stock options expire on June 17, 2035, which is 10 years from the grant date.

What is Rita Jain's role at AVTX according to the Form 4 filing?

According to the Form 4 filing, Rita Jain serves as a Director of Avalo Therapeutics (AVTX), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What is the exercise price of AVTX stock options granted to Rita Jain in June 2025?

The exercise price of the stock options granted to Rita Jain is $4.47 per share.